艾曲泊帕治疗儿童持续性/慢性原发性免疫性血小板减少症停药后持续应答:中国多中心观察性回顾性研究
该多中心回顾性观察研究纳入143例接受艾曲泊帕单药治疗超过2个月的持续性/慢性原发性免疫性血小板减少症患儿,总体应答率为69.2%,其中43.3%达完全应答、25.9%达应答。在35例停药患儿中,71.4%获得停药后持续应答,占全部治疗患儿的17.5%。获得完全应答、更早开始治疗、疗程更长及减量更慢的患儿更易获得停药后持续应答。
要点
- 艾曲泊帕治疗儿童持续性/慢性原发性免疫性血小板减少症总体应答率为69.2%(99/143)。
- 35例停药患儿中71.4%(25/35)获得停药后持续应答,占全部患儿的17.5%(25/143)。
- 获得完全应答的患儿更易获得停药后持续应答(p=0.02)。
核心结论
- 艾曲泊帕在69.2%的持续性/慢性原发性免疫性血小板减少症患儿中产生应答,17.5%的患儿获得停药后持续应答且耐受良好。
- 获得完全应答、尽早开始艾曲泊帕治疗、疗程更长且减量更慢的患儿获得停药后持续应答的概率更高。
研究设计与样本
- 多中心回顾性观察研究,于2022年11月开展,纳入2017年1月至2021年11月期间接受艾曲泊帕单药治疗超过2个月的持续性/慢性原发性免疫性血小板减少症患儿,共143例。
- 收集艾曲泊帕治疗前、治疗期间及治疗后的临床数据;停药后持续应答定义为停用艾曲泊帕后至少6个月不给予救援治疗的情况下维持血小板计数≥30×10^9/L。
主要发现
- 143例患儿中,总体应答率为69.2%(99/143),其中完全应答率为43.3%、应答率为25.9%。
- 在35例分析停药情况的患儿中,71.4%(25/35)在停用艾曲泊帕且未接受额外ITP治疗后获得停药后持续应答,中位随访0.94年(范围0.53-3.8年),相当于全部艾曲泊帕治疗患儿的17.5%(25/143)。
- 与复发患者(n=10)相比,停药后持续应答患者(n=25)的完全应答率更高(80%[20/25] vs 40%[4/10]),从开始治疗到减量的间隔更短(6.4个月 vs 9.4个月),从减量到停药的时长更长(1.1年 vs 0.3年),艾曲泊帕治疗持续时间更长(1.6年 vs 0.5年),p<0.05。
- 获得完全应答的患儿更容易获得停药后持续应答(p=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eltrombopag (ELT) is effective and safe in adult persistent/chronic immune thrombocytopenia (p/cITP); a proportion could achieve a sustained response off treatment (SRoT); however, data on children are lacking. We attempted to analyse SRoT of ELT in children with p/cITP in this study. A multicentre retrospective observational study was performed in November 2022 for children with p/cITP who used ELT alone for >2 months between January 2017 and November 2021. Clinical data of pre-, during and post-ELT were collected. SRoT was defined as maintaining a platelet count of ≥30 × 109 /L without rescue therapy for at least 6 months off ELT. There were 143 patients enrolled; 69.2% (99/143) achieved an overall response of 43.3% and 25.9% achieved complete response (CR) and response (R). Among the 35 patients analysed from whom ELT was withdrawn, 71.4% (25/35) showed SRoT after discontinuing ELT without additional ITP therapy, with a median follow-up of 0.94 (range, 0.53-3.8) years, equal to 17.5% (25/143) in all patients treated with ELT. Compared with the patients with relapse (n = 10), the SRoT patients (n = 25) had a higher rate of CR (80% [20/25] vs. 40% [4/10]), shorter interval time from initiation to taper (6.4 months vs. 9.4 months), longer time from taper to withdrawal (1.1 years vs. 0.3 years) and a longer duration of ELT treatment (1.6 years vs. 0.5 years) with p < 0.05. Patients who achieved CR could attain SRoT more easily (p = 0.02). ELT had a response in 69.2% of children with p/cITP and 17.5% of them attained SRoT with good tolerance. The patients who achieved CR and began ELT treatment as early as possible, with a longer treatment duration and slower tapering, had a higher probability of SRoT.
引用
- Wang Z, Wang L, Liu Y, et al. Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol. 2023. PMID: 37128832. doi:10.1111/bjh.18842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。